5{-(1R)-4-Cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-N-propyl-1,2,4-oxadiazole-3-carboxamide | 348624-25-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5{-(1R)-4-Cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-N-propyl-1,2,4-oxadiazole-3-carboxamide
• 英文别名: (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-N-propyl-1,2,4-oxadiazole-3-carboxamide；5-[(3R)-6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl]-N-propyl-1,2,4-oxadiazole-3-carboxamide
• CAS: 348624-25-9
• 化学式: C₁₈H₃₀N₄O₄
• 分子量: 366.461
• InChiKey: IALSBWBRIDYNGC-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate 在 正丙胺 、 盐酸羟胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.5h， 生成 5{-(1R)-4-Cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-N-propyl-1,2,4-oxadiazole-3-carboxamide
  参考文献：
  名称：

  Procollagen C-proteinase inhibitors

  摘要：

  它们及其盐、溶剂合物、前药等，其中取代基具有此处提及的值，是Procollagen C-蛋白酶（PCP）抑制剂，并在由PCP介导的疾病中具有用途。

  公开号：

  US20010021718A1

文献信息

• [EN] OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS<br/>[FR] ACIDES OX(ADI)AZOLYL-HYDROXAMIQUES UTILISES COMME INHIBITEURS DE LA PROCOLLAGENE C-PROTEINASE
  申请人：PFIZER LTD

  公开号：WO2001047901A1

  公开（公告）日：2001-07-05

  Compounds of formula (I) and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

  式(I)化合物及其盐、溶剂化物、前药等，其中取代基具有此处提及的值，是前胶原C-蛋白酶（PCP）抑制剂，在由PCP介导的疾病中具有应用价值。
• 3-Heterocyclylpropanohydroxamic acids
  申请人：——

  公开号：US20030119807A1

  公开（公告）日：2003-06-26

  Compound of formula (I): 1 and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

  化合物公式(I)的化合物及其盐、溶剂合物、前药等，在所述取代基具有所述数值的情况下，是前胶原C-蛋白酶（PCP）抑制剂，并在由PCP介导的疾病中具有应用价值。
• 3-heterocyclylpropanohydroxamic acids
  申请人：Bailey Simon

  公开号：US06897306B2

  公开（公告）日：2005-05-24

  Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

  式(I)的化合物及其盐、溶剂合物、前药等，其中取代基具有本文提到的数值，是胶原前蛋白C-蛋白酶（PCP）抑制剂，可用于由PCP介导的疾病。
• Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents
  作者：Simon Bailey、Paul V. Fish、Stephane Billotte、Jon Bordner、Doris Greiling、Kim James、Andrew McElroy、James E. Mills、Charlotte Reed、Robert Webster

  DOI：10.1016/j.bmcl.2008.10.036

  日期：2008.12

  Succinyl hydroxamates 1 and 2 are disclosed as novel series of potent and selective inhibitors of procollagen C-proteinase (PCP) which may have potential as anti-fibrotic agents. Carboxamide 7 demonstrated good PCP inhibition and had excellent selectivity over MMPs involved in wound healing. In addition, 7 was effective in a cell-based model of collagen deposition (fibroplasia model) and was very effective at penetrating human skin in vitro. Compound 7 (UK-383,367) was selected as a candidate for evaluation in clinical studies as a topically applied, dermal anti-scarring agent. (C) 2008 Elsevier Ltd. All rights reserved.
• OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1240152B1

  公开（公告）日：2004-12-08